![Karen Knudsen describes her vision for ACS](https://cdn.cancerletter.com/media/2021/09/03152412/47-32-quilt-4x3-1.jpg)
![Karen Knudsen describes her vision for ACS](https://cdn.cancerletter.com/media/2021/09/03152412/47-32-quilt-4x3-1.jpg)
Cover Story
Conversation with The Cancer Letter
On Aug. 5, two months into her job as CEO of the American Cancer Society, Karen Knudsen was in Burlington, VT, checking out the Hope Lodge—the third one she visited since taking the job.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for September 2021
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Our challenge: To find zen in chaos
- Foundations acquire a critical new role as federal funding for cancer research falters
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”